Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025
Comparing clinicopathological profile and treatment outcomes in younger versus older patients with carcinoma oral tongue - a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mahajan Shaifali, Ahlawat Parveen, Tandon Sarthak, Purohit Sandeep, Prasai Gerim, Lohani Sauharda, Gairola Munish
Аннотация
BACKGROUND: The rising incidence of oral tongue squamous cell carcinoma (OTSCC) among younger patients has raised concerns about a distinct clinical course in younger adults. This study investigated differences in demographics, clinicopathological profiles, and outcomes, such as locoregional control (LRC), distant metastasis-free survival (DMFS) and overall survival (OS), between younger (≤ 40 years) and older (> 40 years) OTSCC patients.
MATERIALS AND METHODS: A retrospective analysis of 650 OTSCC patients treated between 2008 and 2022 at a cancer centre was conducted. Patients were categorized into younger (≤ 40 years, n = 189) and older (> 40 years, n = 461) groups. All patients underwent upfront surgery followed by adjuvant treatment. Univariate and multivariate analyses were performed to identify prognostic factors for LRC, DMFS and OS.
RESULTS: There was no significant difference in 3-year LRC (younger: 53.7%, older: 56.5%, p = 0.300), DMFS (younger: 57.9%, older: 61.5%, p = 0.339), and OS (younger: 59.4%, older: 62.7%, p = 0.397), median LRC (younger: 49.1 months, older: 55.7 months, p = 0.863), median DMFS (younger: 75.4 months, older: 69.1 months, p = 0.749) or median OS (younger: 75.4 months, older: 72.4 months, p = 0.831). Tumour grade, margin status, perineural invasion (PNI), nodal stage (pN), and extracapsular extension (ECE) were significant predictors of LRC and OS, but age was not.
CONCLUSION: Age is not an independent prognostic factor for OTSCC outcomes. Younger patients should not receive more aggressive treatment solely based on age. Treatment should follow standard care protocols for all OTSCC patients.
MATERIALS AND METHODS: A retrospective analysis of 650 OTSCC patients treated between 2008 and 2022 at a cancer centre was conducted. Patients were categorized into younger (≤ 40 years, n = 189) and older (> 40 years, n = 461) groups. All patients underwent upfront surgery followed by adjuvant treatment. Univariate and multivariate analyses were performed to identify prognostic factors for LRC, DMFS and OS.
RESULTS: There was no significant difference in 3-year LRC (younger: 53.7%, older: 56.5%, p = 0.300), DMFS (younger: 57.9%, older: 61.5%, p = 0.339), and OS (younger: 59.4%, older: 62.7%, p = 0.397), median LRC (younger: 49.1 months, older: 55.7 months, p = 0.863), median DMFS (younger: 75.4 months, older: 69.1 months, p = 0.749) or median OS (younger: 75.4 months, older: 72.4 months, p = 0.831). Tumour grade, margin status, perineural invasion (PNI), nodal stage (pN), and extracapsular extension (ECE) were significant predictors of LRC and OS, but age was not.
CONCLUSION: Age is not an independent prognostic factor for OTSCC outcomes. Younger patients should not receive more aggressive treatment solely based on age. Treatment should follow standard care protocols for all OTSCC patients.